ebook Munafa Stock Market Course + Intraday & FNO calls  

       

NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE

Novo Nordisk A/s Complete list of announcements declared & dividend announcements by Novo Nordisk A/s NVO

Novo Nordisk A/s NVO listed on NYSE and deals in Health Care Major Pharmaceuticals

Announcements and dividends declared by Novo Nordisk A/s NVO

Natco beats rivals with Rs 1,290 semaglutide launch as Novo Nordisk patent expires
Natco Pharma introduces a new, affordable semaglutide injection in multidose vials. This launch coincides with the patent expiry of the innovator's drug. The company aims to make this treatment more accessible to patients across India. Other pharmaceutical
Announcement as on 20 March 2026

Novo Nordisk says new weight-loss drug not as potent as Eli Lilly's; stock sinks

Announcement as on 23 February 2026

Sun Pharma gets DCGI nod for Wegovy-like weight loss drug, launch after Novo Nordisk's patent expiry
Sun Pharma has received DCGI approval to launch Noveltreat, a generic semaglutide injection for chronic weight management in India. This GLP-1 receptor agonist will be available after patent expiry, offering a crucial treatment option for India's growing o
Announcement as on 23 January 2026

Veeva Expands Partnership With Novo Nordisk Through Vault CRM Adoption
(RTTNews) - Veeva Systems Inc. (VEEV), a cloud software company, on Wednesday said Novo Nordisk's International Operations business unit has committed to use Veeva Vault CRM, expanding the companies' existing partnership.
Announcement as on 07 January 2026

HC seeks Novo Nordisk's reply on Natco plea to revoke patent
The Delhi High Court has asked Novo Nordisk to explain why its patent for the diabetes and weight loss drug semaglutide should not be cancelled. Natco Pharma filed the petition. Novo Nordisk's patent expires in March. This has sparked patent disputes as ot
Announcement as on 06 January 2026

Announcements by Novo Nordisk A/s first page | Next page | Prev page |

NVO Novo Nordisk A/s current price & indicator signals

Moving Averages for Novo Nordisk A/s

  • 5Day Average: 45.9
  • 12Day Average: 46.25
  • 20Day Average: 46.33
  • 50Day Average: 47.94
  • 100Day Average: 45.7
  • 150Day Average: 44.3
  • 200Day Average: 46.42

NVO Indicators & signals

Indicator MACD (12,26,9)

46.25, 46.73, -0.39
Indicator MACD is in negative zone

Indicator ADX (14)

8.82, 21.23, 25.34
Indicator ADX is indicating that momentum is weak.
Momentum is towards selling.

Indicator RSI (14)

Current RSI is: 48
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of NVO Novo Nordisk A/s are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
01 Tue Sep 2026 45.12 45.07 to 46.16 -0.46% 0.89 times
31 Mon Aug 2026 45.33 44.95 to 45.61 -0.61% 0.72 times
28 Fri Aug 2026 45.61 45.41 to 46.21 -1.41% 0.81 times
27 Thu Aug 2026 46.26 45.70 to 46.33 -1.97% 1.23 times
26 Wed Aug 2026 47.19 46.87 to 48.04 -3.02% 0.84 times
25 Tue Aug 2026 48.66 47.56 to 48.66 3.71% 1.47 times
24 Mon Aug 2026 46.92 46.57 to 47.30 0.39% 0.92 times
21 Fri Aug 2026 46.74 46.34 to 47.17 1.3% 1.03 times
20 Thu Aug 2026 46.14 46.11 to 46.90 -0.71% 0.92 times
19 Wed Aug 2026 46.47 45.23 to 47.20 1.66% 1.18 times
18 Tue Aug 2026 45.71 44.53 to 46.07 1.85% 0.88 times
17 Mon Aug 2026 44.88 44.68 to 45.79 -2.2% 1.09 times

Videos related to: NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE

Hindi Video Most Important Stock Market Video. No Success Without This Formula

Hindi Video What Is Needed To Succeed In Stock Markets

NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE

 

Back to top